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ABSTRACT
Mirza, S., 2007. Crystallization as a Tool for Controlling and Designing Properties of
Pharmaceutical Solids.
Dissertationes bioscientiarum molecularium Universitatis Helsingiensis in Viikki,
25/2007, 64 pp.
ISBN 978-952-10-4182-2 (paperback), ISBN 978-952-10-4186-0 (pdf), ISSN 1795-7079
The ability to deliver the drug to the patient in a safe, efficacious and cost-effective
manner depends largely on the physicochemical properties of the active pharmaceutical
ingredient (API) in the solid state. In this context, crystallization is of critical importance
in pharmaceutical industry, as it defines physical and powder properties of crystalline
APIs. An improved knowledge of the various aspects of crystallization process is
therefore needed. The overall goal of this thesis was to gain better understanding of the
relationships between crystallization, solid-state form and properties of pharmaceutical
solids with a focus on a crystal engineering approach to design technological properties
of APIs. Specifically, solid-state properties of the crystalline forms of the model APIs,
erythromycin A and baclofen, and the influence of solvent on their crystallization
behavior were investigated. In addition, the physical phenomena associated with wet
granulation and hot-melting processing of the model APIs were examined at the
molecular  level.  Finally,  the  effect  of  crystal  habit  modification  of  a  model  API  on  its
tabletting properties was evaluated.
The thesis enabled the understanding of the relationship between the crystalline forms
of the model APIs, which is of practical importance for solid-state control during
processing and storage. Moreover, a new crystalline form, baclofen monohydrate, was
discovered and characterized. Upon polymorph screening, erythromycin A demonstrated
high solvate-forming propensity thus emphasizing the need for careful control of the
solvent effects during formulation. The solvent compositions that yield the desirable
crystalline form of erythromycin A were defined. Furthermore, new examples on solvent-
mediated phase transformations taking place during wet granulation of baclofen and hot-
melt processing of erythromycin A dihydrate with PEG 6000 are reported. Since solvent-
mediated phase transformations involve the crystallization of a stable phase and hence
affect the dissolution kinetics and possibly absorption of the API these transformations
must be well documented. Finally, a controlled-crystallization method utilizing HPMC as
a crystal habit modifier was developed for erythromycin A dihydrate. The crystals with
modified habit were shown to posses improved compaction properties as compared with
those of unmodified crystals. This result supports the idea of morphological crystal
engineering as a tool for designing technological properties of APIs and is of utmost
practical interest.
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1. INTRODUCTION
The vast majority of active pharmaceutical ingredients (APIs) are formulated as solid
dosage forms due to their convenience and excellent patient compliance, with most
marketed products containing API(s) and/or excipients in the crystalline state (Byrn,
1999). The bioavailability of a solid dosage form is strongly dependent on physical
properties of the actual API to be formulated (crystalline form, morphology, particle size
distribution). In addition, the processability (filtration, drying, milling, granulation,
tableting) is determined by the physical properties of the material (Table 1).
Table 1 Effect of solid-state properties defined by crystallization process on
properties of an API and drug product (modified from Shekunov and York, 2000)
Solid-state properties Affected bulk and/or performance properties
Structural Solid-state form,
crystallinity, crystal
defects
Physical and chemical stability; hygroscopicity;
solubility, dissolution rate and bioavailability; all
aspects of processing
Dimensional Crystal size
distribution,
crystal habit, surface
structure
Processing behaviour (agglomeration, flow
properties, compaction); particle permeability
(adsorption); bioavailability; consistency and
uniformity of the dosage form
Chemical Chemical purity,
residual solvent,
microbial purity,
chiral purity
Toxicity; chemical, physical and enantiotropic
stability
Electrical Electrostatic charge
distribution
Agglomeration and flow properties
Crystallization, particularly crystallization from solution, is the bottom-up unit
operation in the production of pharmaceutical solids and is invariably used as a separation
and purification procedure. In addition to purity (chemical and structural), physical
properties of a material are originally determined when it is crystallized. Even minor
changes in crystallization conditions can significantly alter the crystal and powder
properties, namely particle size, shape, surface characteristics, purity and defect structure
followed by thermodynamic and mechanical properties. These effects have been
recognized as the major batch-to-batch and source variation problems leading to
inconsistency of the final tablet properties (Shekunov and York, 2000). Nevertheless, the
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significance of crystallization processes has been underestimated in the pharmaceutical
industry. Overall, unfavourable and inadequately understood physical properties are often
at the root of many of the problems that delay new drug approvals by regulatory agencies;
and manufacturing issues, stock-outs and product recalls are costly consequences of poor
control over materials properties (Gardner et al., 2004; Yu et al., 2004). Crystallization
can therefore be regarded as the first step in formulation and must be properly designed to
achieve adequate control of the required characteristics and the desired pharmaceutical
performance. This concept is being increasingly recognised by the pharmaceutical industry
and driven under new regulatory directives encouraging quality by design (FDA, 2004a;
FDA, 2004b; ICH, 2005a; ICH, 2005b). In addition, a thorough understanding of solid-
state properties of APIs, particularly phenomenology of polymorphism,  is  relevant  for
intellectual property rights (IPR) protection.
Crystallization  at  the  molecular  level  is  a  supramolecular  process  (Davey,  2004).  In
this context, the properties of the solid state are dependent on molecular recognition
(Doherty, 1996). Understanding of a solid structure allows the crystal designer to
manipulate the crystal chemistry in order to optimise specific performance characteristics.
Within the pharmaceutical industry, where bringing an innovative drug molecule to the
market often exceeds US $800 million (DiMasi et al., 2003), the crystal engineering
approach (Desiraju, 2001) may offer the valuable tool for tailoring physicochemical
properties of already marketed APIs. Pharmaceutical co-crystals (crystalline complexes of
two or more noncovalently bound neutral molecular constituents) are an example on how
crystal-engineering concept can be utilised to address physical and intellectual property
issues in the context of drug development and delivery (Remenar et al., 2003;
Vishweshwar et al., 2006; Blagden et al., 2007). In future, crystal engineering may be
applied to design a molecule that is guaranteed to crystallize in a particular polymorphic
form under physiological conditions (Desiraju, 2001).
In-depth knowledge of crystallisation processes and solid-state properties of APIs is
therefore clearly requested to ensure consistent quality of dosage forms and implement
new and existing crystal engineering approaches to drug delivery system design.
THEORY AND LITERATURE REVIEW
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2. THEORY AND LITERATURE REVIEW
2.1 Pharmaceuticals as molecular crystals
2.1.1 Classification
Solid materials can exist as crystalline or amorphous phases, depending on the presence or
absence of long-range three-dimensional (3-D) order, respectively. Due to their high
stability and ease of processing, most pharmaceuticals are produced as molecular crystals
that are composed of molecules held together by weak attractive forces such as van der
Waals forces or hydrogen-bonding (Byrn, 1999; Datta and Grant, 2004). Molecular
crystals  may exist  as single molecular entities or as molecular adducts (multicomponent
phases) (Haleblian, 1975) and may show polymorphism or isomorphism.  Polymorphism is
the ability of a substance to exist as two or more crystalline phases with different
molecular arrangements and/or conformations (Bernstein, 2002), while isomorphism is the
capability of different chemical species to form crystals with identical molecular
arrangements  (Myerson,  1999).  A  crystalline  form  that  contains  either  stoichiometric  or
nonstoichiometric amounts of solvent, in addition to molecules of the major component, is
termed solvate; if the incorporated solvent is water, a term hydrate is used. The major
component and incorporated solvent are often termed the host and guest, respectively. The
ability of a substance to form solvates is sometimes referred to as pseudopolymorphism
(Byrn, 1999; Vippagunta et al., 2001) or solvatomorphism (Brittain, 2007).
On  the  basis  of  the  location  of  water  in  their  structures,  crystalline  hydrates  are
classified into three categories (Morris and Rodríguez-Hornedo, 1993; Morris, 1999). (1)
Isolated site hydrates, in  which  water  molecules  are  separated  from  each  other  by  host
molecules, can usually be distinguished during non-isothermal dehydration by sharp DSC
endotherms and a narrow TGA weight loss range. The dehydration of isolated site
hydrates often leads to amorphous and unstable products. (2) A distinctive feature of ion-
associated hydrates that contain ion coordinated water is dehydration at high temperatures
due to the strong metal-water interaction. (3) In channel hydrates water molecules are
localized in lattice channels and form hydrogen bonded chains. These hydrates are usually
THEORY AND LITERATURE REVIEW
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Figure  1 General classification of possible solid phases of an organic chemical compound
(adapted from Haleblian, 1975).
discriminated by continuous dehydration beginning at relatively low temperatures during
non-isothermal dehydration. Clathrates are a special type of molecular adducts in which
the guest molecules occupy, fully or partially, cages in the crystal lattice of the host
without specifically interacting with the host molecules. For instance, the ability of
cyclodextrine to form clathrates is widely used for solubility enhacing of poorly water
soluble APIs (Grattan, 1995).  Crystal habit (morphology) describes the overall external
shape of a particular crystal, differences in external crystal shape being not necessarily
indicative of a change in the internal structure. General classification of possible solid
phases of organic molecular solids is presented in Fig. 1.
The different crystal packing and lattice energies associated with different polymorphs
and solvates give rise to measurable differences in physical properties (thermodynamic,
spectroscopic, kinetic, surface, and mechanical) (Grant, 1999). For pharmaceutical
industry, the impact polymorphism and solvatomorphism may ultimately have on
therapeutic efficacy, toxicity, and bioavailability as well as processing (Haleblian and
McCrone, 1969; Brittain and Fiese, 1999; Byrn et al., 2001; Morris et al., 2001) is of
major concern. These concerns are reflected by an increased regulatory interest in
thorough physico-chemical characterization of APIs (Grant and Byrn, 2004; Byrn et al.,
1995; ICH, 1999).
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2.1.2 General aspects of the formation of polymorphs and solvates
Although the majority of organic crystals (~85%) tend to exist  as single entities (Nangia
and Desiraju, 1999),  the prevalence of solvatomorphism among APIs has been
documented more frequently – 29% of APIs are known to form hydrates and 10% form
other solvates (Griesser, 2006). The ease of formation and subsequent stabilization of
molecular solids can be explained by Kitaigorodskii’s close packing theory
(Kitaigorodskii, 1973), which states that the molecules within the crystal will attempt to
pack so that the amount of unoccupied space is minimized and the number of close
contacts with neighbouring molecules maximized. Hence, the desire to pack efficiently
generally provides the driving force towards selected structural arrangements in molecular
materials (Doherty, 1996), especially those that are dominated by van der Waals
interactions. In some cases, however, energetically favourable hydrogen bonds
compensate for the loss of spatial efficiency and thus stabilize the crystal structure with
large voids (Bernstein, 2002).
Some classes of drugs (e.g., steroids, antibiotics, and sulfonamids) are particularly
prone to forming solvates. This is probably due to cavities or large channels that often
exist in the crystal structures of these compounds. The size and chemical environment of
the cavity or channel determine the type of incorporated solvent molecule as well as kind
of interaction between guest and host (Guillory, 1999). When the solvent molecules are
trapped, as in clathrates, the solvate is more stable than when the solvent molecules are
located along channels in the lattice.
Water represents the smallest guest molecule in solvates. Owing to this feature, it can
easily fill structural voids. In addition, due to multidirectional hydrogen bonding capability
the water molecule is ideal for linking a majority of drug molecules into stable crystal
structures. Hydrates with one mole-equivalent water (monohydrates) are the most common
form of hydrate in organic APIs (Morris, 1999).
Among organic solvents, methanol, benzene, dichloromethane, ethanol and acetone are
the most common solvate-forming molecules. However, when a solvent usage correction
is applied, dimethylformamide, dimethyl sulfoxide and dioxane are most commonly
involved in solvate formation due to their ability to form multiple hydrogen bonds with
organic molecules. As a result, the extrusion of the solvent during the aggregation and
nucleation process becomes disadvantageous from an enthalpic viewpoint and the solvent
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remains an integral part of the nucleating crystal. The fact that only a minority of organic
compounds form solvates is attributed to the entropic gain in eliminating solvent
molecules during nucleation (Nangia and Desiraju, 1999).
2.1.3 Stability relationships between crystalline phases
The thermodynamic relationship between different phases of a substance is governed by
Gibbs’ phase rule:
P + F = C + 2                                                           (1)
where C is the number of components, P is the number of phases that exist in equilibrium,
and F is the number of degrees of freedom of the system. If two polymorphs of a single
substance are in equilibrium (i.e. P = 2 and C = 1), the variance F equals unity, meaning
that at a given pressure, usually atmospheric, the temperature of the system is fixed at the
transition temperature, Tt.  This  dictates  that  only  one  phase  can  exist  at  any  given
temperature and pressure, except at the transition temperature, in which case two phases
(e.g. polymorphs) exist in equilibrium.
Polymorphic systems
A phase transition, the process of transformation of one polymorph into another, may
occur at a given pressure by changing the temperature. The ability of a system to undergo
such spontaneous change is measured by the Gibbs free energy (G), which is given by
G = H TS
(2)
where H is the enthalpy, T is the absolute temperature and S is the entropy. A reduction in
Gibbs free energy is the thermodynamic driving force for a phase transition. A reversible
phase transition is characteristic of enantiotropy (Fig. 2A), whereas an irreversible phase
transition  is  typical  of monotropy (Fig. 2B). For enantiotropic systems, the transition
temperature is less than the melting point of either polymorph; the energy of the transition
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on heating is endothermic;
each enantiotrope has its
own temperature range of
stability; and the melting
enthalpy and density of
the higher-melting form
are lower. Examples
demonstrating such
behaviour are
carbamazepine and
metochlorpramide (Burger
and Ramberger, 1979; Giron, 1995). For monotropic systems, only one form is stable (i.e.
has the lower free energy content) at all temperatures; the unstable to stable form
transformation is exothermic; and the stable form is less soluble and has the higher
melting point and density (Burger and Ramberger, 1979; Burger, 1982). An example of
this type of system is chlorampehicol palmitate (Giron, 1995).
Solvated systems
The stability of solvates depends, in addition to pressure and temperature, on the partial
pressure (activity) of the solvent of crystallization above the solid (Grant and Higuchi,
1990). Analogously to an energy diagram
for polymorphic systems, the stability range
of solvate and unsolvated form can be
established using a van’t Hoff plot (natural
logarithm solubility versus reciprocal
temperature plot) (Shefter and Higuchi,
1963). The relationship between free energy
and an ideal solubility of a solid is given by:
   DG = RT  ln X (3)
or
ln X =
TR
H
R
S 1ff
×
D
-
D (4)
Energy (G, H)
Temperature
HII
 Tt Tm,I Tm,II
DHt
HI
HII
Temperature
GI
GII
II
I
Energy (G, H)
GII
HI
Tm,II Tm,I
GI
II
I
BA
Figure  2 Energy diagrams showing relationship between
enantiotropes (A) and monotropes (B). Modified from Burger
and Ramberger, 1979.
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b
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1/T (K)
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Anhydrate
Lower
hydrate
Higher
hydrate
Figure  3 Solubility diagram for a system of
different solvates showing transition
temperatures, Tt1 and Tt2, between the
anhydrate and the hydrates. Modified from
Shefter and Higuchi, 1963.
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where DSf and DHf are the entropy and enthalpy of fusion respectively, and R is the
gasconstant. A negative slope of a van’t Hoff plot is equal to DHf/R, while an intercept
yields DSf/R for each phase.  It  is  generally accepted that a solvate is  the most stable and
thus the least soluble form in its own solvent. Therefore, aqueous solubility (and hence
stability) order for solvated systems is typically following: stable hydrate < metastable
hydrate < anhydrate < solvate with organic solvent, as illustrated in Fig. 3.
Desolvated solvates
Desolvation of a solvate may result in one of three types of reaction product, specifically a
crystalline anhydrate, amorphous solid or an isomorphic desolvate. An isomorphic
desolvate (or desolvated solvate) forms when
solvent is removed from a specific solvate but the
crystal structure is essentially retained (Byrn et al.,
1994). By definition, an isomorphic desolvate can
only be obtained via the isostructural solvate.
Hence, it is of importance to refer to the parent
solvated structure when naming the desolvated
structure (Pfeiffer et al., 1970). If there already
exists an anhydrous crystalline form of the
molecule, the desolvated solvate can also be
regarded as a polymorph (Morris, 1999), although this is a matter of some debates in the
literature (Griesser, 2006).
The resulting voids in the crystal lattice after solvent loss reduce packing efficiency of
isomorphic desolvates leading to a higher energy (metastable) state. For this reason, the
isomorphic desolvate is usually stable only at low partial pressure of an incorporated
solvent or low humidity. The internal energy of the desolvate can be reduced by processes
that increase packing efficiency, such as sorption of small guest molecules (resolvation) or
structural relaxation (reducing the unit cell volume) (Stephenson et al., 1998; Stephenson
and Diseroad, 2000). Overall, the main consequences of the loose packing efficiency are
reduced thermodynamic and chemical stability, and extreme hygroscopicity (Fig. 4) of the
isomorphic desolvate.
Relative humidity (%)
Figure 4 An example of moisture
sorption/desorption behaviour of
an isomorphic desolvate system
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The model APIs applied in this thesis, baclofen and erythromycin, are structurally
diverse, slightly water soluble, hydrate forming compounds. Baclofen (BF) (Fig. 5A)  is  a
derivative of g-aminobutyric acid and is a potent antispastic agent, while erythromycin
(Fig. 5B) is a mixture of macrolide antibiotics produced by fermentation of strains of
Saccharopolyspora erythrea. Erythromycin A (EM) is the main component, but during
fermentation several related substances such as erythromycins B, C, D, E, F, N-oxide and
N-demethylerythromycin A are formed in small amounts (REF), with erythromycin A and
B being isomorphous (Stephenson et al., 1997). In addition, degradation products such as
pseudoerythromycin A enol ether, formed in alkaline medium, and anhydroerythromycin
A and erythromycin A enol ether, which are formed under mild acidic conditions, may
also be present.
EM dihydrate is an example of isomorphic desolvate systems. While it exists as a
stoichiometric hydrate when first isolated from the crystallization medium, under non-
equilibrium conditions deficiency of the solvent of crystallization leads to
nonstoichiometric characteristics (Cox et al., 1971; Stephenson et al., 1998; Chen et al.,
1999). This means that the degree of its dehydration is a function of the relative humidity
or temperature and equilibration of the dehydrated dihydrate is rapid
and reversible. Worth noting is that to date there are no
specifications in any pharmacopoeias concerning this isomorphic
transition of EM dihydrate and only its maximum
OH
O
Me
O
O
O
MeMe
Et
O
Me
Me
O
Me
OR2
OH
Me
O Me
N(Me)2
HO
R1
Me
OH
B
Content (%)
EM Brutto
Formula
MW R1 R2 Ph.
Eur.
USP
A C37H67NO13 734 OH CH3
93–
102*
85–
100.5*
B C37H67NO12 718 H CH3 max 5 max 12
C  C37H67NO13 720 OH H max 5 max 5
*Sum of the percentages of erythromycin A, B and C
Figure 5    Structural formula of baclofen (A) and general structural formula and composition of
commercial erythromycin (B).
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water content is limited (6.5 and 10% according to Ph. Eur. and USP, respectively).
Meanwhile, varying water activity throughout processing and the lifetime of the
compound causes repeatable dehydration-hydration cycles, which are assumed to be a
major source of batch-to-batch variations and batch failures of EM products (Bauer,
1999). This indicates that solid-state behaviour of this molecule is not adequately
understood including the regulatory level.
2.2. Crystallization from solution
Crystallization  is  defined  as  a  phase  change  that  results  in  the  formation  of  a  crystalline
solid (Myerson, 1999). The most common type of crystallization is crystallization from
solution, in which a material that is a crystalline solid at a temperature of interest is
dissolved in a solvent while crystallization is induced by changing the state of the system
in some way that reduces the solubility of the solute. Classically, this kinetic process is
described in terms of two distinct steps, nucleation and crystal growth. The properties of
the crystals obtained are the result of the kinetic relationship between these two processes.
The goal of this review is therefore to introduce basic concepts of nucleation and crystal
growth from solution and impact of these processes on the properties of pharmaceutical
materials.
2.2.1 The driving force for crystallization
Crystallization can take place over the concentration range limited by the equilibrium
composition of the system at specified conditions
(Fig.6). Thermodynamic equilibrium refers to the
solutions saturated with respect to the solute (i.e.,
the concentration of the solution represents the
solubility value for that solid phase); the rates of
dissolution and crystallization are equal under these
conditions. A solution with solute concentration
below the saturation limit (shown by solid line) is
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Figure 6 Schematic solubility/
supersolubility diagram.
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termed undersaturated and  existing  crystals  will  dissolve.  In  order  for  crystallization  to
occur, the system must be brought into a non-equilibrium state where the concentration of
the solute exceeds its equilibrium concentration (i.e., the solution is supersaturated). The
driving force for crystallization is therefore the degree of supersaturation, expressed as the
difference in concentration between the supersaturated and saturated solutions. The most
common methods to create supersaturation in a solution include temperature change,
solvent evaporation, chemical reaction, pH change, and alteration in solvent composition.
The metastable limit (dashed line) defines the compositions at which spontaneous
crystallization occurs and the region bounded by the solubility curve and the metastable
limit is termed metastable zone. The metastable zone width depends on purity of the
system, thermal history of solution and density of foreign particles present in the solution
and is of practical importance since it defines the working area for designed
crystallizations (Beckmann, 2000).
2.2.2 Nucleation processes
Crystal nucleation involves the aggregation of dissolved molecules in the supersaturated
solution into organized clusters (embryos) thus developing a surface that separates them
from the environment. This process can be split into two main categories (Zettlemoyer,
1969; Mullin, 2001): (1) primary nucleation, when no crystals are initially present in the
solution, and (2) secondary nucleation, when crystals of the solute are already present or
are deliberately added to the solution as seeds. Primary nucleation is further classified into
homogeneous nucleation, which occurs
spontaneously in bulk solutions, and
heterogeneous nucleation,  which  occurs  at
interfaces or surfaces and may be induced by
foreign particles. Homogeneous nucleation rarely
occurs in large volumes (greater than 100 µl), as
most solutions contain random impurities which
may induce nucleation (Perepezko, 1994;
Gunton, 1999). Although heterogeneous and/or
secondary nucleations are commonly
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Figure 7 Schematic diagram
showing metastable zone width
with respect to nucleation type.
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encountered in practice, homogeneous nucleation forms the basis for classical nucleation
theory. Metastable zone widths with respect to nucleation type are schematically shown in
Fig. 7.
Classical Nucleation Theory
The classical nucleation theory (Volmer, 1939; Gibbs, 1948; Nielsen, 1964) was originally
derived for the condensation of vapor into liquid and has been extended to crystallization
from solutions. According to this theory, the free energy change  (DGtotal) for a cluster
undergoing a phase transition is given by
DGtotal = DGsurface + DGvolume (5)
where DGvolume is a volume free energy term that proportional to the cube of the radius and
favours aggregation of molecules and DGsurface is  a  surface  free  energy  term  that
proportional to the square radius of the cluster and favours the dissolution of molecular
clusters. Thus for a small radius, r, where the positive surface energy predominates, the
nucleus is unstable and tend to dissolve. Eventually, the cluster attains the critical size (r =
rc) at which the surface term and volume term exactly balance. At this point the total free
energy of the cluster attains a maximum, which corresponds to the activation free energy
of nucleation (DG*) (Fig. 8). Thus, supersaturation is required to overcome the free energy
barrier to nucleation. After this stage,
the cluster becomes viable and is
termed a nucleus, which eventually
grows  into  a  crystal.  For  a
polymorphic system, the polymorph
that nucleates first is thought to come
from  the  cluster  that  exhibits  the
fastest growth rate as a result of its
lowest  free  energy  barrier  to
nucleation. However, the nature of the
polymorph that eventually crystallizes
is determined by the combination of
rc
DG*
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 e
n
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DGtotal
DGvolume ~ -r3
Radius, r
DGsurface ~ r2
Figure  8 Schematic plot of Gibbs free energy
change of clusters during the process of
molecular aggregation. Modified from Lohani
and Grant, 2006.
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Flat
Figure  9 A three-dimensional crystal surface
showing three type of growth sites.
Kink
Step
Growth units
the relative nucleation rates and the relative crystal growth rates of the polymorphs
(Bernstein et al., 1999).
Recent theoretical and experimental evidence however suggests that the classical
nucleation theory may not be qualitatively correct (Oxtoby, 1998; Davey et al., 2002;
Vekilov, 2004; Parveen et al., 2005). The most critical limitation is that cluster size is the
only criterion for whether concentration fluctuations become nuclei; thus this theory fails
to recognized randomly oriented molecular aggregates that do not correspond to the solid
crystals and organized clusters (Lee and Myerson, 2006). In addition, latest studies suggest
that nucleation of solutes from solution is a two-step process (ten Wolde and Frenkel,
1997; Galkin and Vekilov, 2000; Vekilov, 2004; Chattopadhyay et al., 2005): the creation
of a droplet of a dense liquid, metastable with respect to the crystalline state, followed by
ordering within this droplet to form a three-dimensional lattice structure.
In pharmaceutical industry, understanding and controlling nucleation is of importance,
for example, when crystallizing specific crystalline forms or stabilizing supersaturated
solutions (e.g. in transdermal formulations).
2.2.3 Crystal growth
Once formed, nuclei begin to grow larger through the addition of solute molecules to the
crystal lattice, and this stage of crystallization process is known as crystal growth. Crystal
growth is a multi-step process (Rodríguez-Hornedo and Murphy, 1999, Davey and
Garside, 2000), which includes (1) transport of a growth unit (a single molecule, atom,
ion, or cluster) from or through the bulk
solution to an impingement site, which is
not necessarily the final growth site (i.e.
site of incorporation into the crystal); (2)
adsorption of the growth unit at the
impingement site, (3) diffusion of the
growth units from the impingement site to
a growth site, and (4) incorporation into
the crystal lattice. Desolvation of the
growth unit may take place anywhere in
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steps 2–4 or the solvent may be adsorbed with the growth unit. The relative importance of
each step depends on the surface structure of the crystals and the properties of the solution
(Meenan et al., 2002).
Based on their ability to capture arriving growth units, three types of crystal surfaces
(and  thus  growth  sites  created  by  these  surfaces)  can  be  differentiated  (Hartman  and
Perdock, 1955) (Fig. 9):  kink,  step  and  flat  faces,  which  provide  three,  two  and  one
surface bond(s), respectively. Assuming the linear relationship between a face growth rate
and the total binding energy of a growth unit to the surface, the final shape of a crystal is
defined by the slowest growing flat faces. Crystal growth theories are therefore concerned
with the mechanisms by which these faces grow.
Crystal growth theories
The possible pathways by which a growth unit passes from solution to become integrated into
the crystal lattice are known as growth mechanisms. Two mechanisms are considered to be of
relevance to the actual process of growth on crystal faces – two-dimensional (2-D) nucleation
and screw dislocation (Davey and Garside, 2000). Two-dimensional nucleation, also called the
Birth and Spread (B+S) model, occurs when nuclei at the crystal surfaces act as sources of
steps that allow for the further incorporation of growth units (Volmer, 1922). This mechanism
has gained popularity, since it is simple yet based on firm thermodynamic and kinetic
principles. However, it mainly accounts for the crystal growth observed at high
supersaturations (Rodríguez-Hornedo et al., 2006a).
An alternative mechanism suggested by Burton, Cabera and Frank (BCF) (Burton et al.,
1951) underlines the assumption that growth occurs by flow of steps across the surface. Screw
dislocation, a common crystal defect formed when one region of the crystal is pushed up
through one  (or  more)  unit  cells  relative  to  another  region, can be an infinitive source of
these steps, onto which oncoming growth units can be incorporated. Since screw dislocations
exist on crystal faces at low supersaturations level, the model suggest that the growth can take
place under realistic conditions.
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2.2.4 Crystal lattice imperfections
Industrially produced crystals are always polycrystals composed  of  a  great  number  of
small crystals whose lattices show numerous imperfections. There are four major types of
lattice imperfections (Zhang and Grant, 1999; Mullin, 2001): (1) zero-dimensional or point
defects (vacancies, interstitials, and substitutional), (2) one-dimensional or line defects
(edge, slip, and screw dislocations); (3) two-dimensional or surface defects (grain, tilt, and
twist boundaries), and (4) three-dimensional or phase defects (solid, liquid or gaseous
inclusions).
In addition to affecting crystal growth, these imperfections are known to influence the
physicochemical (e.g. chemical reactivity, dissolution rate) and mechanical (e.g. elasticity,
plactisity) properties of materials (Boldyrev et al., 1979; Burt and Mitchell, 1981; Chow
and Grant, 1989; Forbes et al., 1992; Mullin, 2001). The nature and frequency of the
crystal defects may change as a function of mechanical (e.g. grinding or milling) or
thermal stress applied to the material. Milling, for example, can result in the formation of a
large number of vacancies and dislocations (Fabbiani and Pulham, 2006), ulimately
leading to the disappearance of long range order and crystallinity (amorphisation). Hence,
crystal defects are thought to be an important source of batch-to-batch and lot-to-lot
variations giving rise to processing problems and poor and inconsistent product
performance (York, 1983; Shekunov and York, 2000). Quantitatively, crystal
imperfections are commonly assessed in terms of crystallinity (York, 1992) or entropy
changes (Grant and York, 1986a; Grant and York, 1986b).
2.2.5 Crystal habit
At equilibrium, the external shape of a crystal, also termed habit, form or morphology, is
determined by its internal structural symmetry and this idealized equilibrium (minimum-
energy) form is known as the Wulff form. Experimentally obtained crystals however
exhibit a growth habit since the crystal growth is a nonequilibrium process. The
equilibrium form can be achieved through an aging process, which involves solvent-
mediated dissolution and regrowth of the crystal faces equilibrated in a saturated solution
over time (Stranski and Honigmann, 1950; Saska and Myerson, 1987).
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In  crystallography,  to  relate  a  surface  structure  to  the  crystal  structure  a  system  of
Miller  Indices  is  used.  These  define  the  orientation  of  the  surface  in  relation  to  the
crystallographic unit cell, the smallest three-dimensional volume element from which the
crystal can be constructed. Each face is designated with three integers, h, k, l, which are
the inverse of intersections of that face with the crystallographic axes a,  b and c; faces
which  are  parallel  to  a  crystal  axis  are  given  the  Miller  index  of  0.  In  practice,  crystal
morphology is usually described in terms of length, width and thickness. Within the
pharmaceutical industry the classifications of crystal shapes adopted by either British
Standrad (BS 2955:1993) or the US Pharmacopoeia (monograph 776) (Table 2) are
commonly used for routine microscopical examination of solid materials.
Table 2 Classification of common crystal morphologies for pharmaceutical solids
accepted by the US Pharmacopoeia
Morphology Description Diagram
Equant Crystal with similar length, width, and
thickness
Flakes Thin, flat crystals of similar width and
length
Plates Flat, tabular crystals with similar width
and length but thicker than flakes
Laths Elongated, thin and blade-like crystals
Needles Acicular, thin and highly elongated
crystals having similar width and breadth
Columnar Elongated, prismatic crystals with greater
width and thickness than needles
2.3 Crystallization and designing properties of pharmaceuticals
The quality of crystallization depends on a large number of factors that influence crystal
nucleation and growth, including the composition of the crystallization medium and the
process(es) used to generate supersaturation and promote crystallization. The
crystallization of pharmaceutical solids should be designed to control the crystalline form,
purity, yield, crystal size distribution, and crystal shape. Apart from yield, all these
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qualitaties have a profound effect on stability, processability and/or bioavailability of the
product (see Table 1). This section of the thesis is focused on general approaches used to
generate and tailor properties of pharmaceutical solids.
2.3.1 Polymorph screening
Polymorph screening, which includes generation and characterization of different solid
phases, is an obligatory procedure specified by the International Conference on
Harmonization (ICH) guideline for new APIs (ICH, 1999). The ultimate goal of this
procedure is to select a form with the appropriate balance of critical properties for
development into the drug product (typically, the most thermodynamically stable). In
addition, precise knowledge of the polymorphic behaviour of an API is needed for
intellectual property protection and design of robust larger-scale crystallization processes.
Although several flow charts and decision trees have been suggested (Byrn et al., 1995),
there is no universally accepted guideline on how to perform polymorph screening. In
general, the procedure must be tailored to the substance investigated and the actual
product development phase (Huang and Tong, 2004; Hilfiker et al., 2006). For example, a
screening performed early in development simply aims to identify the thermodynamically
stable form and hydrates, and thus slow crystallization experiments should be favoured
over fast ones. Later product development phases require identification of all relevant
solid forms.
Crystallization from solution (cooling or evaporative, as well as slurry conversion) and
recrystallization from neat API (sublimation, thermal treatment, crystallization from the
melt, grinding, and thermal desolvation) are most often employed in screening
experiments (Guillory, 1999; Morissette, 2004). To increase the probability of discovering
all relevant forms, the multiparameter space that contributes to solid form diversity (see
Table 3) should be covered as broadly as possible. This is usually achieved by designing a
rational set of the process variables (Huang and Tong, 2004; Hilfiker et al., 2006). With
respect to crystallization solvent, for example, such set typically encompasses (1) solvents
with broad distribution of properties (Gu et al., 2004), (2) potential solvents of synthesis,
purification and processing, (3) potential solvents for formulation (e.g. polyethylene
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glycols). In addition, crystallizations from water and water-solvent mixtures are usually
included in the screens to generate hydrates.
Table 3 Process variables affecting crystallization outcome. Modified from Morissette et al., 2004
Crystallizing phases Crystallization method
Polymorphs/
solvates
Salts/
co-crystals
Cooling
crystallization
Evaporation Precipitation Slurry
conversion
Solvent
composition
Degree of
supersaturation
Additive type
Additive
concentration
Counter-ion type
Acid/base ratio
Solvent/Solvent
combination
Degree of
supersaturation
Additive type
Additive
concentration
pH
Ionic strength
Heating rate
Cooling rate
Maximum
temperature
Incubation
time
Incubation
temperature
Evaporation
rate
Evaporation
time
Carrier gas
Surface-
volume ratio
Anti-solvent
type
Rate of anti-
solvent
addition
Temperature
of anti-
solvent
addition
Time of anti-
solvent
addition
Solvent type
Incubation
temperature
Incubation
time
Thermal
cycling and
gradients
Recently developed high-throughput crystallization technologies (Peterson et al., 2002;
Hilfiker et al., 2003) utilize a combination of robotic handling together with small volume
crystallization reactors and allow for more rapid and comprehensive exploration of
multivariate crystallization space. In addition, several innovative techniques have been
reported, such as capillary crystallization (Childs et al., 2004a), laser-induced
crystallization (Myerson and Garetz, 2002) and sonocrystallization (Ruecroft et al., 2005)
that promote nucleation and hence discovery of alternate crystalline forms. Finally, a
number of attempts to develop ab initio polymorph screening algorithms has been reported
(Karfunkel and Gdanitz, 1992; Chaka et al., 1996; Ferrari et al., 2006). However, success
using computing approach is limited (Gavezzotti, 1994) and thus theoretical prediction of
crystal structures still remains an admirable long-term goal.
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2.3.2 Directed crystallization of specific crystalline forms
Exploring Ostwald's law of stages
The key thermodynamic variables that affect the kinetics of crystal nucleation and growth
are supersaturation and interfacial energy. This implies that resulting the crystalline form
may vary with degree of supersaturation and type of crystallizing solvent.  The  effect  of
supersaturation on crystallization of polymorphs has been described by the empirical
Ostwald's law of stages (Ostwald, 1896), which states that the most soluble and the least
stable form crystallizes first. Theoretically, it can be justified by a higher nucleation rate of
the least stable form arising from a smaller critical nuclei radius (Shekunov and Grant,
1997). Hence, fast crystallization or crystallization at high supersaturations will
preferentially lead to a metastable form. However, Ostwald’s law of stages is not universal
because  the  appearance  and  evolution  of  solid  phases  are  determined  by  the  kinetics  of
nucleation and growth under specific experimental conditions (Cardew and Davey, 1985;
Davey et al., 1997). The above concept is also applicable for solvates and hydrates
(Khankari and Grant, 1995).
Altering crystallizing solvent, temperature or pH
The selectivity of solvent on the formation of specific polymorphs is well recognized. This
effect is largely kinetic (Khoshkhoo and Anwar, 1993) and depends on the nature and
strength of solute-solvent interactions (Weissbuch et al., 1999; Weissbuch et al., 2005).
More precisely, preferential solvent adsorption on the nuclei’s surface alters the activation
energy of nucleation for a particular polymorph (see Fig. 7) by decreasing the surface free
energy and consequently total free energy of these nuclei (Gu et al, 2002). Hence, in one
solvent one form might be obtained preferentially while the other one may crystallize in a
second solvent under exactly the same crystallization conditions. The relative stability of
polymorphs is not affected by the solvent as the latter can only interact with the surface
and the surface contribution to the free energy of a crystal is generally negligible (Hilfiker
et al., 2006).
Overall, it has been demonstrated that the crystallization outcome is under
thermodynamic control when the concentration and temperature of crystallization is
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significantly above or below the transition temperature (Fig. 10), while near the transition
temperature the resulting polymorph may be significantly influenced by the relative
nucleation rates of the polymorphs and/or specific interaction between a given polymorph
and the solvent (Threlfall, 2000). Therefore, interplay between kinetic and thermodynamic
conditions is usually employed to produce the desired polymorph from different solvent or
solvent systems (Berman et al., 1968; Gu, 2001; Bernstein, 2002). For example,
metastable crystalline solids can be obtained
either by rapid crystallization in a monotropic
system or by temperature change in an
enantiotropic system. Clearly, the solvent is
the decisive factor for the crystallization
outcome if a solvate can be formed with that
particular solvent.  By changing the activity of
water in both miscible and immiscible organic
solvents the desired hydrate can be produced
(Zhu et al., 1996), with lower temperatures
favouring formation of solvates of higher
stoichiometry (Byrn, 1999).
The  pH  of  the  crystallizing  solvent  is  of
particular importance for crystallization of
salts.  In  some  cases,  however,  the  pH  or
polarity of the solvent can be decisive factor for controlling the crystallization of
polymorphs (Byrn et al., 1994; Towler et al., 2004).
Using Additives and Impurities
Impurities (unintentionally present components) and additives (intentionally added
impurities) are also known to affect nucleation via the mechanism described for solvents
(see the previous subsection). The examples of additives employed for controlling
polymorphic outcome of pharmaceuticals include structurally related (tailor-made) organic
molecules (Weissbuch et al., 1991; Mukuta et al., 2005; Lee et al., 2006), polymers (Lang
et al., 2002b; Langevin, 2002) and surface-active agents (Garti and Zour, 1997; Rodríguez-
Hornedo and Murphy, 2004). Polymers and surfactants can also act as crystallization or
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Figure 10 Solubility curves (solid
lines) and metastable zone limits
(dashed lines) for two enantiotrops I
and II. The regions of negligible
solvent effect on the crystallization
outcome are highlighted. Modified
from Threlfall, 2000.
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phase transformation inhibitors in pharmaceutical formulations (Simonelli et al., 1970;
Katzhendler et al., 1998; Airaksinen et al., 2005; Klein et al., 2005; Leveque et al., 2006;
Salameh and Taylor, 2006; Tian et al., 2007). Furthermore, reaction by-products and other
impurities have been recognized to direct polymorph appearance (Blagden et al., 1998),
and in some cases, a metastable one (Davey et al., 1997; He et al., 2001; Gu et al., 2002).
In addition, a variety of inorganic and organic crystal surfaces have been proposed to
control polymorph crystallization (Hooks et al., 2001; Mitchell et al., 2001; Lee et al.,
2005). This approach is based on an epitaxial mechanism when the oriented growth of a
substance on a surface occurs due to the alignment of their lattice parameters. Polymer
heteronucleation is the first combinatorial approach to controlling polymorphism that
directly targets nucleation (Lang et al.,  2002a).  In  this  case,  the  polymer  acts  as  an
additional diversity element to affect the crystallization outcome. This provides the
potential  for  controlling  the  formation  of  established  forms  as  well  as  the  discovery  of
unknown polymorphs without prior knowledge of crystal structure. For example, a fourth
polymorph of carbamazepine was discovered (Lang et al., 2002b) using this approach that,
remarkably, proved more stable that the well-studied trigonal form (Grzesiak et al., 2003).
Seeding
The addition of solid particles (seeds) of the desired phase to a crystallization medium is
known as seeding.  It  is  often  only  reliable  way  to  obtain  the  desired  form  (Beckmann,
2000) and even if an API does not show polymorphism, seeding is frequently applied to
control the crystallization process (Hilfiker et al., 2006). Controlling crystallization
outcomes via seeding relies on the potential of crystal surfaces to promote heterogeneous
or secondary nucleation, while avoiding heterogeneous nucleation mediated by unknown
contaminants (Mullin, 2001). The crystallization of ritonavir polymorphs (Bauer et al.,
2001) is an example of the vivid effects of accidental heterogeneous nucleation where an
insoluble degradation product promoted the nucleation of a more stable polymorph.
Seeding can also be employed for chiral resolution of enantiomers during crystallization
(Collet et al., 1980; Sheldon, 1990; Gu and Grant, 2000). The factors affecting the seeding
effectiveness include seed addition timing and method, seed surface properties, and the
rate of supersaturation generation (Paul et al., 2005).
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2.3.3 Solvent-mediated transformations
The stable crystalline modification is usually preferred to its metastable counterpart for
formulation and processing. However, sometimes a metastable solid phase with greater
thermodynamic activity is chosen due to its better biopharmaceutical performance. The
drawback is that since any system strives to reach equilibrium, a metastable form present
in the formulation is prone to a solvent-mediated transformation upon processing (e.g. wet
granulation) and/or storage. Such transformation is driven by the solubility difference
between the two phases when the metastable phase is in contact with the saturated solution
and allows for the transition from a metastable to the stable phase. Based on this, solvent-
mediated transformations are widely used to produce the most stable polymorph (Gu et al.,
2001).
A solvent-mediated transformation involves three consecutive steps (Cardew and
Davey, 1985): (1) initial dissolution of the metastable phase into the solution to reach and
exceed the solubility of the stable phase; (2) nucleation of the stable phase; (3) crystal
growth of the stable phase coupled with the continuous dissolution of the metastable
phase, with step (2) or (3) being usually the slowest one. When step (2) is rate-
determining, the overall transformation is influenced by factors that affect nucleation (e.g.
solubility and solubility differences between the phases, processing temperature, contact
surfaces, agitation, and soluble excipients/impurities). When step (3) is the rate-controlling
step, the kinetics of the conversion is determined by the solubility difference, solid/solvent
ratio,  agitation,  processing  temperature,  particle  size  of  the  original  phase,  and  soluble
excipients/impurities (Zhang et al., 2004).
This kind of transformation may also occur during solubility measurements,
dissolution studies and accelerated stability tests in hydrated systems (Khankari et al.,
1998; Aaltonen et al., 2006; Tian et al., 2007). The rate of transformation may be
influenced by retarding the rate of dissolution of the less stable species e.g., by introducing
specific  impurities  that  act  as  inhibitors.  Finally,  the  effect  of  formulation  on  the  phase
transformations cannot be overlooked. For example, solid dispersions or high viscosity
lipid-based formulations can be ideal environments for the formation of a more stable
crystalline form (Martinez-Oharriz et al., 1999; Huang and Tong, 2004). Potentially,
solvent-mediated polymorphic transformations can be exploited for exclusive production
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of a metastable form of an API by utilizing solvents in which the transformation is slow
(Okamoto et al., 2004).
2.3.4 Particle size control
Particle size is one of the physicochemical properties influencing the performance of the
drug product and its manufacturability (http://www.ich.org) (see Table 1). Accordingly,
Table 4 Particle size distribution of pharmaceuticals with respect to dosage form
 and route of administration (according to Shekunov et al., 2007)
Particle Size
(mm)
Dosage form or
route of administration
min max
Oral granules 200 1000
Oral depot 50 200
Intraperitoneal 10 50
Nasal 5 20
Aerosols 1 5
Ocular 0.1 2.5
Intravenous/intramuscular 0.2 2
Gene delivery 0.2 0.9
Transdermal 0.06 0.6
Long-circulating (brain, tumor) 0.06 0.2
Lymphatic 0.01 0.06
the  design  of  particle  size  distribution  with  respect  to  dosage  form  and  administration
route  (Table 4) as well as consistent particle size control during crystallization are
required. In this context, production of micro- and nanosized particles represents the most
challenging area (Chow et al., 2007).
Supersaturation is the key factor affecting particle size as the number of molecules
necessary to achieve an effective nucleating cluster is inversely proportional to the level of
supersaturation (Rodríguez-Hornedo and Murphy, 1999). Therefore, the number of
crystals produced increases with the supersaturation, whilst the size of crystals decreases.
A number of crystallization techniques for generating micron- and submicron-sized
particles – for example, impinging jet crystallization (Midler et al., 1994) and solvent
shifting (Horn and Rieger, 2001) - are based on fast nucleation under high supersaturation
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conditions. Potential problems associated with such nucleation-driven processes include
lack of control over the resulting solid form (e.g. amorphous material or an undesired
polymorph), broad particle size distribution, high surface area, low bulk density,
agglomeration and aggregation, the risk of large batch-to-batch variations, and solvent or
impurity entrapment (Mullin, 2001; Paul et al., 2005).
Other crystallization-based approaches to controlling crystal size include seeding
(Bohlin and Rasmuson, 1992; Braatz et al., 2006), precipitation in the presence of growth-
retarding additives (Rasenack et al., 2003; Mathiowitz et al., 2004), sonocrystallization
(Dennehy, 2003; Price and Kaerger, 2005; Bucar and MacGillivray, 2007), confined
crystallization (Yano et al., 2000; Lee et al., 2005), and supercritical fluid crystallization
(Hanna and York, 2006).
Supercritical Fluid Crystallization
Supercritical fluid (SCF) technologies enable single step crystallization of particulate
pharmaceutical materials with precisely controlled characteristics such as solid-state form,
particle size, shape and crystallinity (Loth and Hemgesber, 1986; Kordikowski et al.,
1999; Shekunov and York, 2000; Edwards et al., 2001; Shekunov et al., 2006). This
control is achieved by utilising SCFs (gases and liquids at temperatures and pressures
above their critical points) as solvents with tunable viscosity, density, and solvation
strength (Tom and Debenedetti, 1991). For pharmaceutical applications, the most widely
used SCF is carbon dioxide because of its low critical temperature (31.1 oC), attractiveness
for heat sensitive materials including biomolecules, as well as being non-flammable, non-
toxic, GRAS (’generally regarded as safe’) status and inexpensive (York, 1999).
For pharmaceutical materials, the most commonly used modifications of SCFs
processing have been precipitation from supercritical solutions composed of SCF and
solute(s) and precipitation from saturated solutions using SCF as a non-solvent or
antisolvent. The former process involves dissolving the solute in a SCF, followed by a
rapid  expansion  of  the  SCF  solution  across  an  orifice  to  cause  a  supersaturation  of  the
solute, homogeneous nucleation and thereby particle formation (Shekunov, 2004). The
main weakness of this method is the poor solubility of most drugs in SCFs (Shah, 2006).
The second approach utilizes a similar concept to the use of antisolvents in solvent-based
crystallization processes and overcomes the solubility limitation by dissolving the drug in
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a conventional solvent. In addition, it allows for the efficient separation (by
decompression) of the antisolvent from both the solvent and solid products (Palakodaty
and York, 1999; Kordikowski et al., 2001).
Ostwald ripening
Theoretically, the particle size distribution should ultimately change towards that of a
monosized dispersion when the solid remains in contact with its own saturated solution as
larger crystals tend to grow (or ripen) at the expense of smaller ones. This process of
crystal coarsening is known as “Ostwald ripening” (Ostwald, 1896) and is driving by the
solubility difference between smaller and larger crystals; small crystals (>1 mm) have
excess free energy (i.e. higher solubility compared with larger crystals) due to their high
surface curvature and thus larger crystals are more energetically favoured. Ripening can
take place, for instance, in suspension during crystallisation or wet granulation. Control of
this process is important in cases where small particle size is needed (e.g aerosol
products). In order to retard this process, additives (e.g. gelatin or carboxymethyl
cellulose) are commonly used in industry (Mullin, 2001). In contrast, this process can be
accelerated by the use of controlled temperature fluctuations (temperature cycling).
2.3.5 Morphological crystal engineering
The growth habit of a crystal is the result of the relative growth rates of its faces, with the
morphological importance of a crystal’s face being inversely proportional to its growth
rate. The growth rates of the different crystal faces are determined by intermolecular
interactions between molecules in the crystal as well as by a number of external
parameters such as solvent, supersaturation, temperature, and impurities (Myerson, 1999).
Changes in any of these may lead to significant modifications in crystal morphology. This
gives rise to crystal habit diversity of a chemical entity grown under various crystallization
conditions and provides the basis for morphological crystal engineering.
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Varying degree of supersaturation and temperature
Owing  to  anisotropic  growth  rates  of  surfaces,  the  growth  habit  of  a  crystal  reflects  the
supersaturation in which the crystal grows (Okutsu et al., 2003). This effect can be
expressed as:
y/x = k?Sn (6)
where y/x is the ratio of crystal length to width; k is a coefficient of proportionality
depending on diffusion; ?S is the degree of supersaturation (moles/1000 moles of solvent,
at the moment of nuclei formation); and n is a number that depends on the crystallographic
classification and chemical composition of the substance (Grzymek, 1937). Thus, a system
at very high supersaturation may produce a vast quantity of small, elongated microcrystals
over a very short timescale, whilst a low supersaturation solution is likely to produce larger,
granular-shaped crystals over a longer period (Haleblian, 1975). The size and habit of many
crystalline products are particularly sensitive to degree of supersaturation (Ristic et al., 2001).
The effect of temperature on the crystal morphology can be described by Arrhenius
equation dictating linear relationship between the crystal growth rate and temperature.
Hence, crystals tend to be more isotropic in their shape when grown at higher temperatures
(Davey and Garside, 2000).
Influence of solvent
Solvents may influence the rate of crystal growth through their effects on solution
properties (e.g. density, viscosity, diffusivity), solubility of the crystallizing species and
surface-solvent interactions. However, it is generally accepted that the underlying
mechanism for the solvent action as crystal habit modifier is preferential adsorption at
specific crystal faces which will inhibit their growth as removal of bound solvent
possesses an additional energy barrier for continued growth (Weissbuch et al., 1991). As a
result, the crystallization from a solvent with high structural affinity to the crystallizing
species may yield fine, symmetrical or elongated crystals due to the delayed growth of all
or selected crystal faces, respectively (Tiwary, 2006).
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Crystal habit modification by changing the solvent has been widely used (Haleblian,
1975; Davey et al., 1982; Marshall and York, 1989; Marshall and York, 1991; Garekani et
al., 2001; Karunanithi et al., 2006). However, this approach is limited by the  solvent
toxicity and cost, crystallization efficiency and the purity requirements of the final
product. Hence, it is not always possible to find a suitable solvent that yields a desirable
habit.
Employing additives
Similar to solvents, additives control crystal shapes by virtue of their structural
relationships with the crystal surfaces in question and the decisive mechanism takes place
when they are adsorbed on the crystals faces (Mersmann et al., 2001). Additives can be
classified into three categories based on their chemical nature (Rodríguez-Hornedo 1990).
The first includes low-molecular-weight inorganic compounds that are active mainly in
ionic systems. The second class is composed of low-molecular-weight organic substances
(e.g. citric or succinic acids) or substances with similar structures to the crystallizing
solute but possessing additional functional groups. These adsorbates are generally
incorporated into the crystal at the surface, introducing lattice strains that markedly
influence the apparent solubility of the developing faces. Polymeric materials and surface-
active agents that are active for both ionic and non-ionic systems constitute the third
group. Additives may adsorb generally upon all crystal faces, reducing the rate of
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Figure 11 A schematic showing changes in crystal morphology via selective
adsorption of an additive/impurity/solvent onto specific crystal faces. Modified
from Weissbuch et al., 1999.
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crystallization to zero, or, upon selective faces, leading to a change in morphology of the
developing crystals. Because additives may affect the crystallization kinetics in low
concentrations (<10-3), this approach is frequently used to modify the crystal habit of
pharmaceuticals (Michaels and Colville, 1960; Fairbrother and Grant, 1978; Chow et al.,
1985; Williams-Seton et al., 2000; Garnier et al., 2002; Shekunov et al., 2003; Jarmer et
al., 2005; Kuldipkumar, 2006). A mechanism of morphological change due to preferential
adsorption of an additive (or solvent) is illustrated in Fig. 11.
2.3.6 Improving solubility and dissolution rate
The dissolution rate can sometimes be enhanced by crystallizing poorly soluble APIs in
aqueous solutions containing surfactants or water-soluble polymers as additives (Chiou et.
al., 1976; Naggar et al., 1980; El-Bary et al., 1990).  This  effect  has  been  attributed  to
improved wettability due to traces of adsorbed additive in the crystals. In addition, the
deposition of additive molecules onto the crystal during crystal growth might produce a
defect in the crystal structure making the crystal thermodynamically unstable and hence,
faster dissolving (Chiou et al., 1976). The same effect can be achieved by using
structurally-related additives (Fairbrother and Grant, 1978). Alternatively, in situ
micronization during crystallization (Rasenack and Müller, 2002b) and crystal habit
modification (Haleblian, 1975; Blagden et al., 2007) may improve the dissolution rate of
poorly water-soluble APIs.
An emerging approach to enhancing the solubility of APIs is the formation of
cocrystals (Vishweshwar et al., 2006), where crystalline complexes of two or more neutral
molecular constituents are bound together in the crystal lattice through noncovalent
interactions (primarily hydrogen bonding). Cocrystallization can be performed by
evaporation of a heteromeric solution, cogrinding the components, sublimation, growth
from the melt, or slurry technique (Blagden et al., 2007). Two main benefits associated
with this approach are the theoretical capability of all types of molecules, including
weakly ionisable and non-ionizable, to form cocrystals, and the existence of numerous
potential counter-molecules for cocrystal synthesis (Vishweshwar et al., 2006). Examples
of the pharmaceutical cocrystals reported include caffeine (Trask et al., 2005;
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carbamazepine (Rodríguez-Hornedo et al., 2006a), fluoxetine hydrochloride (Childs et al.,
2004b), ibuprofen (Walsh et al., 2003), and itraconozole (Remenar et al., 2003).
2.3.7 Crystal morphology in relation to pharmaceutical processes and
dosage form performance
A number of formulation- and dosage form-related properties (e.g. bulk density,
flowability, compressibility, filterability, suspension stability, wettability, dissolution rate)
can vary with crystal habit (York, 1983; York, 1992; Rasenack and Müller, 2002a;
Tiwary, 2006). Equidimensional crystals such as cubes or spheres are usually preferred in
industry as they have better handling and processing characteristics. For instance, such
crystals demonstrate better flow properties and minimum aggregation due to their loose
packing and low bulk density (Bandyopadhyay and Grant, 2000; Carstensen, 2001; Sun
and Grant, 2001). Crystals with a high-aspect-ratio, however, were shown to be
advantageous for pulmonary drug delivery demonstrating a tendency to deposit more
effectively into the deep lung (Chikhalia et al., 2006). On the other hand, needle-like
crystals are complicated to inject through a fine needle (Haleblian, 1975) and tend to clog
the pores in the filter medium in filtration processes (Lee and Myerson, 2006). Therefore,
morphological crystal engineering should be considered as a valuable tool to enable
material with optimal physical properties for a specific formulation.
The effect of crystal habit on tabletting behaviour can be linked to the relative
orientation of the crystallites during compression (Shell, 1963; Bandyopadhyay and Grant,
2002). Certain crystal habits (e.g. plates, rods or needles) tend to pack preferentially with
their longer dimension(s) oriented normal to the compression axis forming a layered
structure. Such a structure often exhibits low lateral stress transmission characteristics and
results in a weak compacts (Windheuser, 1963; Bandyopadhyay and Grant, 2002). In
contrast, more equidimensional crystals have a propensity to orient randomly and
demonstrate overall reduced anisotropy during compression leading to better tabletting
performance. The crystals habit of drugs to be administered in high doses (e.g.
erythromycin A base) is of special concern since compression properties of the tabletting
mass will be dominated by the API. Additive-induced crystal habit modification may also
favour mechanical properties of the material by introducing lattice strain (Fairbrother and
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Grant, 1978; Chow et al., 1984; Byrn et al., 1994) and hence reducing the energy required
for  plastic  deformation  (Alderborn and Nyström, 1995; Feng and Grant, 2006). The latter
underlines the fact that at fundamental molecular level mechanical properties of the
material are primary defined by internal structure of the crystal (Roberts et al., 1995; Sun
and Grant, 2001; Bandyopadhyay and Grant, 2002; Wildfong et al., 2007).
The dissolution rate can vary with the habit because differences in surface chemistry of
the crystal faces give rise to differences in their surface free energy (Lee and Myerson,
2006). Thus modified crystal habit can be exploited to increase the dissolution rate of
poorly-water soluble drugs.
Finally, it is worth mentioning that processing and formulation procedures may induce
changes in the crystal morphology of an API and/or excipient(s) (York, 1992; Yoshinari et
al., 2002; Zhang et al., 2004). For example, during drying or wet granulation
supersaturated states are often created which may lead to the crystallization of an API or
excipient(s). In the strictest sense, the excipient is an impurity with respect to the API (or
vice versa) and may serve as a crystal habit modifier (Rodríguez-Hornedo et al., 2006a).
Consequently, the drug-excipient (or excipient-excipient) interactions could have a
tremendous impact on the morphology with an adverse effect on further processing and/or
drug delivery. The similar effect can be observed if an API or excipient is able to undergo
a processing-induced phase transformation resulting in a crystalline form with different
crystal habit. The relationships between crystal habit, processing and dosage form
performance are schematically present in Fig. 12.
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   Processing
(e.g. milling, wet
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Figure 12 Schematic representation of the relationship between
     crystal habit, processing and dosage form performance.
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3. AIMS OF THE STUDY
The overall goal of this thesis was to gain better understanding of relationships among
crystallization, solid-state nature, and properties of pharmaceutical solids. In addition, an
objective was to employ a crystal-engineering approach for designing technological
properties of APIs.
The specific aims were:
1) To study solid-state properties of crystalline forms of the model APIs,
erythromycin A dihydrate and baclofen anhydrate, and to ascertain
interconversion pathways between these forms (Papers I, II, III)
2) To investigate  influence  of  the  solvent  system on  crystallization  behaviour  of
erythromycin A dihydrate (Paper III)
3) To get an insight into hydrate formation and dehydration phenomena of the
model APIs (Papers I and II)
4)  To understand the physical phenomena associated with aqueous wet
granulation of baclofen and solid dispersion formation of erythromycin A with
PEG 6000 (Papers II and IV)
5) To  probe  HPMC  as  a  crystal  habit  modifier  for  erythromycin  A  dihydrate  in
relation to compaction properties (Paper V).
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4. EXPERIMENTAL
Complete experimental details can be found in the original publications (I-V).
4.1. Materials
4.1.1 Active substances
The model APIs investigated in this study were erythromycin A base (EM) (USP) and
baclofen (BF) (Ph. Eur.). EM dihydrate from Sandoz (Italy) (I, V) and EM dihydrate from
Pharmacia & Upjohn (Kalamazoo, MI) (III, IV) and BF anhydrate from PCAS (Finland)
(II) were used as received.
4.1.2. Excipients
Polyethylene glycol (PEG) (PEG 6000; Fluka Chemie AG, Buchs, Switzerland) was
selected as a carrier polymer for solid dispersions (IV). In the crystallization experiments
hydroxypropyl methylcellulose (HPMC) (Methocel E 4000, Dow Chemical Company,
USA) was used as a polymeric additive (V).
4.1.3. Solvents
Purified water (Ph. Eur.) (I–V) and the following analytical-grade organic solvents were
used in the crystallization experiments: methanol (MeOH) (III), ethanol (EtOH) (III, V),
isopropanol (i-PrOH) (III), acetone (Ac) (III) and methylethylketone (MeEtCO) (III).
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4.2 Crystallization and processing of materials
4.2.1 Generation of anhydrous, hydrated, dehydrated and amorphous
phases (I–IV)
EM anhydrate (I, IV) was obtained by slurry conversion from an EM dihydrate aqueous
suspension at ~100 ºC. EM dehydrate (I, IV) was obtained by dehydration of the dihydrate
at 40 ºC. Amorphous EM (IV) was prepared by quench cooling of the melt in liquid
nitrogen. BF monohydrate (II) was crystallized from water.
4.2.2 Polymorph screening (III)
Screening crystallization was performed using an automated 24-slotted reaction block
crystallizer (Variomag 24.4-1, H+P Labortechnik GmbH, Munich, Germany) equipped
with a PC-controlled cryostat (Huber, Offenburg, Germany). EM dihydrate was
recrystallized from solutions (50 ml) in the abovementioned organic solvents or in 1:9,
2:1, and 5:5 (v/v) water-organic solvent mixtures. The crystals harvested were vacuum-
filtered, dried in a vacuum oven at 40 °C for 12 hours, and stored in a desiccator at room
temperature (21 ± 1°C).
.
4.2.3 Additive-controlled crystallization of EM dihydrate (V)
The crystallizations (n=3) were carried out by precipitation technique at ambient
temperature.  A  saturated  solution  of  the  drug  in  ethanol  was  slowly  poured  into  an
aqueous solution of HPMC of varying concentrations under constant stirring and the
experiments were completed at solvent/antisolvent ratio of 1:9 (v/v). The final additive
concentrations in the crystallization medium studied were 0 (hereafter referred to as
reference), 0.1, 0.5 or 1 g/L (V, Table 1).
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4.2.4 Preparation of physical mixtures and solid dispersions (IV)
Physical mixtures were prepared by gently mixing the drug (EM dihydrate) with a carrier
polymer (PEG 6000), using a mortar and pestle at various weight ratios (10:90, 30:70,
50:50, 70:30, and 90:10) and were subsequently used for in situ monitoring of the solid
dispersion formation.
     Solid dispersions were prepared by melting the corresponding physical mixtures of the
drug and polymer with constant stirring in a metallic mortar heated in a water bath and
subsequent quench cooling with liquid nitrogen.
4.2.5 Wet  massing  (II)
Wet massing was carried out using a varying amount of purified water as granulating
liquid (II, Table 1). The wet massing was performed with a mortar and pestle to simulate
the early stages of preformulation, when the amount of a new API is relatively small. The
wetted  mass  was  stirred  thoroughly  and  packed  in  sealed  glass  vials.  The  samples  were
analyzed by XRPD and Raman spectroscopy immediately after water addition as well  as
after 24 h of storage at room temperature.
4.2.6 Preparation of powder compacts (V)
Powder compaction behavior was evaluated with an instrumented eccentric tablet machine
(Korsch EK0, Erweka Apparatebau, Germany). For each experiment, the powder (250±10
mg) was manually poured into a die and compacted at various compression pressures
using flat-faced punches with a diameter of 9 mm. Thereafter crushing strength of the
tablets was measured using a tablet hardness tester (Erweka, Germany). The results are
represented as the mean and standard deviations of three determinations.
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4.3 Physical characterization of materials and phase
transformation monitoring
4.3.1 X-ray Powder diffraction (XRPD)(I–V)
X-ray powder diffraction (XRPD) patterns were measured using a theta-theta
diffractometer (D8 Advance, Bruker AXS GmbH, Karlsruhe, Germany) (I–V). The
experiments were performed in symmetrical reflection mode using a CuKa radiation
source (l=1.54 Å) with Göbel mirror bent gradient multilayer optics. Variable-
temperature X-ray powder diffraction (VT-XRPD) was used to detect temperature-induced
phase transformations (I–III) and in situ monitoring of solid dispersion formation (IV).
4.3.2 Thermal analyses (I–V)
The  differential  scanning  calorimetry  (DSC)  curves  were  obtained  with  a  DuPont
instrument (Model 910S, TA Instruments Inc., New Castle, DE) connected to a data
station (Thermal analyst 2000, TA Instruments Inc., New Castle, DE) (I–V).
Thermogravimetric analysis (TGA) was performed on a Mettler Toledo TA8000
system (Mettler-Toledo, Greifensee, Switzerland) equipped with a TGA850
thermobalance (I–III, V).
A hot stage (FP900, Mettler-Toledo GmbH, Greifensee, Switzerland) mounted on the
optical microscope (Leica Microscopie und Systeme GmbH, Wetzlar, Germany) was used
for visual examinations of temperature induced phase transformations (I, IV).
4.3.3 Microscopy (II–V)
The morphology of the crystals (II, III) and  hydrate formation (II) were examined with an
optical microscope (DAS Mikroskop, Leica Microscopie und Systeme GmbH, Wetzlar,
Germany) equipped with a 3-CCD color camera (Sony XC-003P, K-Vision B.V., Huizen,
Netherlands). The snapshots were captured using WinTV 2000 software (Hauppauge,
London, UK).
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Scanning electron microscopy (SEM) was used for detailed examination of the crystal
morphology (II, V). SEM micrographs were recorded with a Zeiss DSM-820 (Carl Zeiss,
Oberkochen, Germany) scanning electron microscope at an acceleration voltage of 10 kV.
4.3.4 Vibrational spectroscopy (I,II, IV)
Mid-infrared (mid-IR) spectra (IV) were recorded with a Vertex 70 Fourier-transform IR
spectrometer (Bruker optics GmbH, Ettlingen, Germany).
The near infrared (NIR) spectra (II) were measured with a NIR spectrometer
(Control Development Inc., South Bend, IN, USA) with a thermoelectrically cooled
InGaAs diode array detector, tungsten light source and a fiber optic probe.
Raman  spectra  were  collected  using  two  different  instruments.  In  paper  I  a  Kaiser
Holoprobe RXN1/785 Raman module (Kaiser Optical Systems, Inc., Ann Arbor, MI,
USA) coupled via a mono-mode optical fiber to a Leica DMLP microscope (Leica
Microscopie und Systeme GmbH, Wetzlar, Germany) was used, while in Paper II the
spectra were recorded with a process-type Raman spectrometer (Control Development
Inc., South Bend, IN, USA) equipped with a thermoelectrically cooled CCD detector and a
fiber optic probe (RamanProbe, InPhotonics,  Norwood, MA). A 500 mW laser source at
785 nm was used (Starbright 785S, Torsana Laser Technologies, Skodsborg, Denmark).
Both NIR and Raman spectral intensities reported herein were normalized by standard
normal variate (SNV) transformation.
4.3.5  Water sorption/desorption analysis (II)
Samples of BF anhydrate were dried in the oven (Heraeus Vacutherm, Heraeus, Germany)
at 40 °C and 70 mbar for 3 h. The water sorption profile of the powder was determined
gravimetrically after storage at 22 °C at different relative humidities (RHs) (0–95%).
These RH conditions were achieved in vacuum desiccators by using saturated salt
solutions.  The  sample  weight  (n=3)  was  monitored  over  time  until  no  further  weight
change was observed. For the desorption study, samples of the monohydrate were stored at
0% RH.
EXPERIMENTAL
 - 37 -
4.4 Molecular modelling (I,V)
The single crystal X-ray diffraction data for EM dihydrate (Stephenson et al., 1997) were
retrieved from Cambridge Structural Database (CSD). The theoretical powder X-ray
diffraction pattern of EM dihydrate (CSD refcode: NAVTAF) was calculated, and the
Miller index of each diffraction peak was assigned using the Property Prediction Module
of Cerius2. The theoretical growth form was computed by using molecular simulation
software (Mercury, Cambridge Crystallographic Data Center, Cambridge, UK, v. 1.2.1)
according to the Bravais-Friedel-Donnay-Harker (BFDH) theory. The same software was
used for crystal structure visualization.
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5. RESULTS AND DISCUSSION
5.1 Characterization of crystalline forms of model APIs
In this section, the crystalline forms of two APIs, erythromycin A (EM) and baclofen
(BF), have been studied. There has been some confusion in the literature about the solid-
state properties of EM crystalline forms (Bauer et al., 1985; Murthy et al., 1986), since
none of the crystal structures has been solved until recently. In this study, an attempt has
been made to bring physical characterization of unsolvated and several solvated forms of
EM in line with the published crystal structure of EM dihydrate. In addition, the solid-state
properties of the crystalline forms of another drug, BF, are reported for the first time.
5.1.1 Crystalline forms of erythromycin A (I, III, IV)
EM base (see Fig. 5B) can exist in several, with respect to water content, crystalline forms
– the dihydrate, dehydrate, and anhydrate
(Fukumori et al., 1983; Laine et al., 1987,
Stephenson et al., 1997) – with the dihydrate
being the thermodynamically stable form at
ambient conditions (Fukumori et al., 1983). The
experimental X-ray powder diffraction (XRPD)
patterns for the crystalline forms of EM are
shown in Fig. 13.  Obviously  that  reflections
associated with EM dihydrate (III, Table 1) are
sufficiently distinguished from those of EM
dihydrate. Meawhile, EM dehydrate – a stable
form between 60 and 130 ºC or RH<15% and
23 oC (Stephenson et al., 1997) – is isomorphic
to EM dihydrate and thus yields an XRPD
pattern similar to EM dihydrate.
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Figure 13 XRPD patterns of the
three crystalline forms of erythromycin A
(EM). The values (o2q) of the characteristic
diffraction peaks are indicated. Modified
from Paper I.
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EM dihydrate and EM anhydrate were also readily discriminated by their mid-IR
spectra, especially in the C=O stretching region between 1740 and 1700 cm-1 (IV, Fig.
2B).
Raman spectra of the three crystalline forms of EM differed clearly in the spectral
regions around 3100–2800 and 1750–1650 cm-1 (I, Fig. 2C), which correspond to the C-H
and C=O stretching modes (Lin-Vien, 1991), respectively (I, Table 1).
5.1.2 Crystalline forms of baclofen (II)
Baclofen (see Fig. 5A) was found to exist in two crystalline forms, the anhydrate and
monohydrate, as confirmed by multiple analytical techniques. There were distinct
differences in the diffraction profiles of the anhydrate and monohydrate (Fig.14),
indicating that these two solid forms have
unique crystal structures. The most intense
diffraction peaks were observed at 5.8, 17.5,
23.4 and 29.4º 2q for the anhydrate and at 10.7,
16.1 and 21.5º 2q  for the monohydrate.
The mid-IR spectrum of the monohydrate
(II; Fig. 2B) shows a broad band at 3337 cm -
1 that is absent in the anhydrous phase. This
band  corresponds  to  O–H  stretch  vibrations  of
water of crystallization, confirming its presence
in the crystal structure of the monohydrate. The
NIR (II, Fig. 2C;) spectrum of the monohydrate
showed a distinct water absorbance maximum
(due to combination of OH stretching and
bending vibrations (Buijs and Choppin, 1963))
at around 1990 nm, while the anhydrate
demonstrated no absorption bands in this spectral region. The principal differences in the
Raman spectra of the two forms of BF occur between 700–1600 cm-1 and are shown in
Fig. 2D (II).
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Figure 14 XRPD patterns of the
crystalline forms of baclofen reported
with the characteristic diffraction peaks
of the anhydrate and monohydrate
indicated by (*) and (o). Modified from
Paper II.
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In summary, it was shown that the two crystalline forms of BF are readily
distinguished by XRPD and vibrational spectroscopy.
5.2 Solvatomorphism of model APIs
A number of common unit operations (e.g., wet granulation, spray-drying, lyophilisation,
film-coating) in pharmaceutical industry expose APIs and excipients to solvents or solvent
vapors, thus providing  a possibility for a solvent to be incorporated into the crystal lattice.
Since solvate formation is inevitably linked to a significant change in the material
properties, this phenomenon should be systematically studied.
5.2.1 Effect of solvent composition on crystallization behaviour of
erythromycin A (III)
Screening crystallization of EM dihydrate resulted in five crystalline solvates, as verified
by  XRPD,  DSC  and  TGA  –  plate-like  crystals  of  EM  dihydrate  (III, Fig. 6A)  and  EM
ethanolate (EM×EtOH)  (III, Fig. 6D), and needle-shaped crystals of EM acetonate (EM×
Ac), EM methylethylketonate (EM×MeEtCO) (III, Fig. 6B) and EM isopropanolate (EM×i-
PrOH) (III, Fig. 6C).  When  EM  dihydrate  was  crystallized  from  a  non-aqueous  organic
solvent,  or  from 1:9  or  1:1  water–organic  solvent  mixtures,  a  corresponding  solvate  was
formed.  Recrystallization from 2:1 water–organic solvent mixture resulted in plate-like
EM dihydrate crystals with the exception of the water–MeEtCO solvent system, which
yielded only crystals solvated with MeEtCO. Note that none of the solvent systems
yielded EM anhydrate, indicating a high solvate-forming propensity of EM.
The crystals of EM×EtOH and EM×i-PrOH produced unique XRPD patterns, while the
diffractograms of EM×Ac and EM×MeEtCO were very similar (III, Fig.2), suggesting that
the latter two crystalline phases are isomorphous. Given the close relationship between the
molecular structures of Ac and MeEtCO, the relatively small range of their molecular
masses (58.1 and 72.1 g mol-1, respectively) and the same hydrogen bonding capacity,
isomorphism of EM×Ac and EM×MeEtCO is easily explainable. Dirithromycin, a
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semisynthetic macrolide antibiotic, is also known to form isomorphic solvates (Stephenson
et at, 1994). The quantitative characteristics of the XRPD patterns of EM solvatomorphs
are presented in Table 1 (III). In summary, the relationships between all the crystalline
forms of EM studied is schematically presented in Fig. 15.
5.2.2 Desolvation behaviour of erythromycin A solvatomorphs (I, III)
The desolvation behaviour of the solvatomorphs of EM was studied by thermogravimetric
analysis (TGA), differential scanning calorimetry (DSC) and variable temperature XRPD
(VT-XRPD).  Since  the  single  crystal  data  for  the  EM solvates  and  BF monohydrate  are
not available, this information allows for the general features of the solvent association to
be deduced.
Recrystallization from the corresponding
organic solvent or from 1:9 or 1:1 water-
organic solvent mixtures
Recrystallization from the melt at ~150 oC
Storage at
RH>15% and
 ambient temperature
Drying at T > 40 oC
 or storage at
 RH<15%
Aqueous slurry
conversion at
T> 60 oC
Aqueous slurry
conversion
at ambient conditions
EM
dehydrate
EM.Ac EM.MeEtCO EM.EtOH EM.i-PrOH
EM
anhydrate
EM
dihydrate
Figure 15 Phase transformations between the reported crystalline forms of erythromycin A.
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 The desolvation characteristics for the EM solvatomorphs are summarized in Table 5.
All the solvatomorphs demonstrated one-step desolvation, with the exception of EM·EtOH
(I, Fig. 2B and III, Fig. 4). In the latter case, desolvation was a two-step process.
Dehydration behaviour of EM dihydrate was in accordance with that of channel-type
hydrates (Morris, 1999). In particular, smooth dehydration with the early onset was
observed over a wide temperature range (40–100 °C). This result is in a good agreement
with the EM dihydrate crystal structure (Stephenson et al., 1997) indicating water
molecules reside in the lattice channels (I, Fig. 5B).  It  is  this  structural  feature  of  EM
dihydrate that allows for an isomorphous dehydrate to be formed upon dehydration, as was
revealed by VT-XRPD (I, Fig. 2A).
Table 5 Desolvation characteristics of erythromycin A solvatomorphs
Incorporated
solvent
MW
(g mol-1)
Onset
of
desolvation
(oC)
Enthalpy
change
J g-1
TGA
weight loss
(%)
Number of
solvent
molecules/mol
of drug
Acetone 58.1 56.5± 1.4 59 ± 1 7.6 1
Ethanol 46.1 54 ± 1.3
75 ± 2.6
68 ± 1
29 ± 1
19.0 3
Isopropanol 60.1 90.8 ± 1.2 143 ± 5 16.0 2
Methylethylketone 72.1 72.3 ± 1.9 68 ± 1 11.6 1
Water 18.0 50.7 ± 1.9 157 ± 3 4.6 2
The desolvation of Em·EtOH was observed under ambient conditions, as indicated by
the  formation  of  the  opaque  crystals.  This  phenomenon was  attributed  to  the  location  of
the guest molecules in the intersecting solvent tunnels running within the crystal lattice
(Byrn, 1999). The DSC data also supported this assumption. The complete loss of the
solvent of crystallization resulted in the collapse of the host crystal lattice.
The DSC desolvation endotherms of EM×Ac, EM×MeEtCO and EM·i-PrOH were
relatively narrow, with the onset temperatures of the process observed near the boiling
points of the corresponding solvents of crystallization  (Tonset = 57, 59 and 91 oC,
respectively)  (III, Fig. 3). Such desolvation behaviour clearly differs from that of EM
dihydrate and suggests different topology (e.g. isolated sites) of solvent inclusion (Morris,
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1999). Desolvation of these solvates resulted in the formation of amorphous phase, as
revealed by VT-XRPD (III, Fig. 5B and 5C).
5.2.3 Impact of crystal structure on dehydration mechanism of EM dihydrate
(I)
The packing diagram of EM dihydrate (space group P212121)  (I, Fig.5B) shows that the
water molecules are located in the lattice channels parallel to the a-axis. The presence of
large enough channels (I, Fig. 5C), which have an approximately circular cross-section
with a radius about 4 Å (Stephenson et al., 1998), allows easy passage of water molecules
with minimum energy expenditure and minimum disruption of the packing arrangement.
Thus,  it  is  hypothesized  that  the  release  of  water  from  the  EM  dihydrate  crystal  occurs
along these structural channels, as was demonstrated for a number of channel hydrates
(Byrn, 1999).
The unified model for the dehydration mechanism of molecular crystals proposed by
Petit and Coquerel (1996) classifies the process of water departure as: (1) cooperative, (2)
destructive, or (3) possibly reconstructive. If the product phase retains structural
information of the reactant (as in the case of EM dehydrate), the release of water
molecules must occur by a cooperative process through lattice channels of sufficient size
??3.5Å). The data obtained by TGA, where continuous dehydration and a low onset
temperature were observed, are in agreement with this concept. Furthermore, the
cooperative departure of water molecules presumes that the process is anisotropic, and
again our results fit well with this concept. As observed by VT-XRPD, the (015) reflection
plane shows the greatest reduction in interplanar spacing when the crystal is dehydrated.
This effect can be caused by lattice contraction of either the b-axis or the c-axis. In the b
direction, the crystal structure is stabilized against deformation by an intermolecular host–
host hydrogen bond (I, Fig. 5A), while in the c direction several host molecules are
separated by water (I, Fig. 5B). Thus, the c-axis is likely to experience the greatest degree
of contraction upon water loss, providing anisotropic shrinkage of the lattice. Based on the
information presented above, it can be concluded that the dehydration of EM dihydrate
follows II topotactic mechanism (Petit and Coquerel, 1996), where no reorganization of
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the dehydrated phase is required since the whole process is limited to the cooperative
departure of water molecules through the water channels (one-step dehydration).
5.2.4 Hydrate formation of baclofen (II)
The phenomenon of hydrate formation of baclofen was probed using optical microscopy.
Snapshots of the crystals periodically taken during the recrystallization of baclofen
anhydrate from water are shown in Fig. 5 (II). As the dissolution of the acicular crystals of
the anhydrate proceeds (II, Fig. 5A),  the  growth  of  whisker-like  crystals  takes  place  (II,
Fig. 5B), suggesting that the anhydrous phase acts as a nucleation site for the
monohydrate.  Thereafter,  fast  dissolution  of  these  whisker  crystals  was  observed,  and  a
few plate-like crystals of the monohydrate appeared in these crystallization conditions (II,
Fig. 5C).  During  the  cooling  phase  the  monohydrate  was  the  only  form present  (II, Fig.
5D).
It is generally accepted that anhydrous to hydrate phase transformations may occur by
one of two processes when the solid is in contact with water: (i) a solid-solid
transformation in which water molecules are incorporated into the crystal lattice while
remaining in the solid state or (ii) a solvent-mediated process where the anhydrous solid
dissolves and creates the necessary supersaturation for the nucleation and growth of a
hydrate (Cardew and Davey, 1985). Our observations indicate that baclofen anhydrate to
baclofen monohydrate transformation occurs via the second, i.e. solvent-mediated, route.
5.2.5 Dehydration behaviour of baclofen monohydrate (II)
The TGA trace for baclofen monohydrate (II, Fig. 3A) yielded a 7.5% weight loss
(theoretical 8.4 %) in the temperature range of 40–80 ºC, confirming a stoichiometric
drug–water ratio 1:1. Like in the case with the EM solvatomorphs, the low onset of
dehydration suggests that the water molecules are located in the crystallographic channels.
The DSC curve of the monohydrate, superimposed in Fig. 3A (II), is characterized by
two endothermic events. Apart from a dehydration endotherm with the peak maximum at
67.1 ºC, the DSC trace yielded an endotherm at 211.8 ºC. The latter thermal effect
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corresponds  to  the  melting  of  the  anhydrate  (Tmax = 213.3 ºC). This suggests that the
dehydration of the monohydrate leads to the crystalline anhydrate. To verify this
assumption, the dehydration of the monohydrate was also investigated by VT-XRPD over
a temperature range of 25–100 ºC (II, Fig. 3B). The patterns of the sample generated
below 50 ºC compare well with those of the monohydrate. At about 60 °C, the diffraction
profile significantly changes resulting in the pattern similar to that of the anhydrate. Thus,
on the basis of the data obtained by TGA, DSC and VT-XRPD it is deduced that baclofen
monohydrate is a channel hydrate (Morris, 1999), which dehydrates at around 60 ºC with
the formation of the anhydrate. Note that in contrast to EM dihydrate that was observed to
form a metastable form upon dehydration (I, III), no intermediate crystalline or amorphous
form was detected during dehydration of BF monohydrate.
5.3 Effect of processing on crystalline state of model APIs in the
solid formulations
The existence of several solid forms of an API implies that interconversion among these
forms during processing can occur. In this chapter, the physical phenomena taking place
during two simulated processes, solid dispersion formulation by hot-melting (EM) and wet
granulation (BF) are discussed.
5.3.1 Effect of PEG on phase behaviour of erythromycin A dihydrate during
hot-melt processing (IV)
EM dihydrate – PEG 6000 (PEG) solid dispersions produced by hot-melting were used as
model  formulations,  while  the  process  was  simulated  in  VT-XRPD,  DSC,  and  HSM
experiments in order to monitor in situ physical changes in the system. Upon heating from
25 to 135 oC pure  EM dihydrate  was  shown to  undergo  a  single  phase  transformation  –
dehydration to isomorphic EM dehydrate at about 60 oC  (III, Fig. 5A and IV, Fig. 3).
Thermal  treatment  of  the  drug  with  PEG  caused  multiple  phase  transformations  (EM
dihydrate ? EM dehydrate ? EM anhydrate) in the same temperature range, as was
RESULTS AN DISCUSSION
- 46 -
detected by VT-XRPD (IV, Fig. 3) and visually observed by HSM (IV, Fig. 5). The onset
temperature of the additional, EM dehydrate ? EM anhydrate, transition, was seen
between 80–130 oC and was found to depend on the drug-polymer ratio. Specifically, with
increased polymer fraction, the onset temperature of the phase transition decreased.
Physical phase transformations are generally classified as solid-state transformations
and solvent-–mediated transformations (Morris et al., 2001). Because EM dehydrate did
not convert to EM anhydrate in the solid state, the alteration in phase behaviour of EM
was  attributed  to  the  ability  of  PEG  in  promoting  nucleation  and  crystal  growth  of  EM
anhydrate via a solution-mediated route. The mechanism for solution-mediated
transformations includes three steps: (i) dissolution of the less stable phase, (ii) nucleation
of the more stable phase,  and (iii)  growth of the more stable phase (Cardew and Davey,
1985). Due to low melting point of PEG (~60 oC) (IV,  Fig.  4,  trace  (h)),  it  can  act  as  a
solvent (Verheyen et al., 2001) for a higher melting API, thus providing a medium for a
solvent-mediated transformation. Further, at the melting temperature of the polymer,
dehydration of EM dihydrate takes place (IV, Fig. 4, trace (a)) and EM dehydrate (m.p. ~
137 oC) becomes the stable form relative to EM dihydrate. Meanwhile, EM dehydrate is
less stable (and therefore more soluble) relative to EM anhydrate above 60 oC. This
suggests fast dissolution of EM dehydrate in the molten carrier and creation of a
supersaturated solution. The latter provides a thermodynamic driving force for nucleation
and growth of the EM·AH crystals (the least soluble and therefore more stable form above
60 oC). Hence, three subsequent processes – dissolution, nucleation and crystal growth –
are inferred to take place during EM dihydrate and PEG hot-melting, supporting the
assumption that the EM dehydrate ? EM anhydrate transformation is governed by the
solvent-mediated route.
5.3.2 Factors affecting hydrate formation of baclofen during wet massing (II)
The wetting phase of aqueous wet granulation with BF as a hydrate-forming model API
was studied using wet masses with a wide range of moisture content (II,  Table  1). The
hydrate formation was detected off-line using qualitative XRPD and Raman spectroscopy.
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According to the XRPD and Raman results, the rate and extent of hydrate formation of
BF during the wetting process depended on both the amount of water added and contact
time with the granulating liquid. In particular, the onset of hydrate formation was detected
when 0.25 g of water/g of anhydrous BF (i.e. 3 mol of water/mol of BF) was used for the
wet massing, while the conversion to the monohydrate was completed at a moisture level
of 0.63 g/g of anhydrous BF (7 mol of water/mol of BF) (II, Fig. 8A and 8B). In addition,
it was observed that less moisture was needed for the complete transformation when wet
masses were allowed to equilibrate for 24 hours at ambient conditions; in this case, 0.25 g
of water/g of anhydrous BF was sufficient for the anhydrate to entirely convert into the
monohydrate (II, Fig. 8C). Overall, our results showed that relatively high moisture
content  (at  least  3  mol  of  water/mol  of  anhydrous  BF)  was  needed  for  BF  to  start
converting into the monohydrate during the wetting process. For comparison, anhydrous
theophylline was shown to convert to the monohydrate with addition of approximately one
mole/mole of water (Jørgensen et al., 2002).
The hydrate formation of BF is a solvent-mediated transformation, as discussed in the
Section 5.2.4. In accordance with the mechanism of such transformations, the factors
affecting the extent of phase conversion include solubility of a metastable phase in a given
solvent and the amount of the solvent available for dissolving this phase. In terms of wet
granulation, it means that the extent of hydrate formation will be proportional to the
solubility of the anhydrate and the volume of the granulating liquid used (Davis et. al.,
2004).
In agreement with this concept, the degree of anhydrate to monohydrate conversion
increased with more granulating liquid in the present study. In addition, the concept
suggests that, under the identical conditions, a less soluble material will require more
solvent in order to reach the same degree of conversion compared to a more soluble one.
The solubility of BF anhydrate in water was estimated to be approximately 2 mg/ml at
room temperature, while the solubility of theophylline anhydrate is approximately 12
mg/ml at 25 oC (Wikström et al., 2005). Therefore, the larger amount of water needed for
the hydrate formation of BF, compared to that of theophylline, can be partly attributed to
its poor solubility.
Furthermore, BF anhydrate was assumed to possess poor wettability since no phase
transition was observed at high RHs (II, Fig. 6) (theophylline anhydrate, for example,
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converts to the monohydrate at 75% RH (Salameh and Taylor, 2006)). Because material
wetting is a factor governing hydrate formation kinetics (Otsuka et al., 2002), it is clear
that the APIs with poor wettability will require the excessive amount of moisture and/or
prolonged contact with granulating liquid for the hydrate to form. Finally, BF
monohydrate is inferred to be a channel hydrate (see Section 5.2.5) with a dehydration
onset as low as 40 oC (vs. ~60 oC for theophylline (Aaltonen et al., 2007)), assuming low
activation energy for the dehydration. The latter suggests that the dehydration proceeds in
the crystallographic direction with the least resistance to water molecules migration, which
corresponds  to  the  direction  of  water  channels  (Morris,  1999).  In  some  cases,  as  with
caffeine monohydrate (Byrn, 1999), such dehydration pathway allows for efflorescence
and rapid dehydration to take place at room temperature and relative humidities greater
than 50%. Hence, it is possible that BF monohydrate dehydrates during the wet massing,
resulting in a shift of the equilibrium to the initial solid phase.
5.4 Enhancing compaction properties by crystal habit
modification (V)
In pharmaceutical industry, a large number of batch failures are attributed to poor
compaction characteristics of APIs arising from their undesirable crystal habit (York,
1992). For high dose APIs such as EM dihydrate this issue is of special interest since the
most advantageous technique to produce tablets with these APIs is direct compression. In
this study, an attempt was made to enhance the compactibility of EM dihydrate crystals
via morphological crystal engineering.
5.4.1 HPMC as a crystal habit modifier
The scanning electron microscopy (SEM) photographs of EM dihydrate recrystallized in
the absence and in the presence of the additive (hydroxylpropylmethylcellulose, HPMC)
(V, Fig. 2) clearly show a concentration-dependent effect of HPMC on the crystal habit. In
particular, the shape of the crystals grown at a relatively low additive concentration (0.45
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wt%) was similar to the reference sample (V, Fig. 2A) and was rather irregular. Upon
further increase in the additive concentration to 2.25 and 4.5 wt% the plate-shaped (V, Fig.
2B) and elongated plate-shaped (V, Fig. 2C) crystals were produced, respectively. This
result  suggests  that  HPMC  affects  the  growth  rates  of  the  EM  dihydrate  crystal  faces
differently.
5.4.2 Mechanistic considerations of the additive effect on crystallization
Based on the Bravais-Friedel-Donnay-Harker (BFDH) theory, the shape of EM dihydrate
is plate-like, slightly elongated along the b direction, and bounded by faces (002), (011)
and (101) (Fig. 16). The comparison of this model with the observed morphology of the
reference crystals (i.e., grown in the absence of the additive) was complicated due to rather
irregular shape of the latter crystals. In
contrast, it was striking to observe that the
morphology of the crystals grown in the
presence of 2.25 wt% of HPMC (V, Fig.
3B) was in a reasonable agreement with the
model, suggesting that the crystals
achieved a dynamic equilibrium with the
solution.
Considering the general effect of the
additives on crystallization kinetics, it can
be assumed that with addition of HPMC to
the crystallization medium the mean growth
rate is suppressed and altered growth rates
of individual crystal faces results in crystal habit modification. Theoretically, EM
dihydrate should demonstrate the fastest growth along the b-axis, because this direction
has the strongest drug-drug intermolecular interactions (Miroshnyk et al., 2001) and the
shortest unit cell dimensions. The growth rate along the a-axis should be of the same
magnitude, since this direction bears water channels and the drug molecules H-bonded
through  the  water.  While  the  morphology  of  the  crystals  grown  in  the  presence  of  2.25
Figure 16  BFDH model along with the
unit cell of erythromycin A dihydrate crystal.
Modified from Paper V.
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wt% of the additive almost reassembles the BFDH model, an increase in the additive
concentration results in more elongated crystals, apparently with decreased growth rate
along the b-axis. This change in morphology suggests specific interactions between the
polymer and the functional groups on the {011} faces of the crystal.
The well-defined arrangement of molecules on crystal surfaces offers a means to probe
molecular recognition events taking place at interfaces during crystallization. Due to
anisotropy  of  the  EM  dihydrate  crystal  structure,  the  terminating  surfaces  of  the  crystal
differ substantially (V, Table 3 and V,  Fig.  6).  In particular,  the largest  (002) face of the
crystal is the most hydrophobic one, while the (011) face is the most hydrophilic, with the
two water molecules being exposed to this face. HPMC has been previously shown to be
capable of interacting with the drug molecules via H-bonds (Katzhendler et al.,1998; Wen
et al., 2005; Tian et al., 2006). It is therefore assumed that the polymer reversibly interacts
with the ED crystal surfaces, especially with (011) and (101), during crystallization thus
suppressing  overall  crystal  growth.  At  relatively  low  concentrations  of  the  additive,  this
effect is hindered due to an insufficient number of polymer molecules. With increased
additive concentration, more polymer molecules are available and the probability of the
drug-polymer interactions is higher. The preferred adsorbtion of HPMC at the {011}
crystal faces leads to retarded crystal growth in the b direction  and  this  effect  is
macroscopically evident as elongated EM dihydrate crystals.
5.4.3 Impact of crystal habit on compaction behaviour
Mechanical properties of the powdered material can roughly be assessed in terms of
compact strength as a function of applied compaction stress (Riippi et al., 2000). In order
to estimate the consequences of the crystal habit modification on the compactibility of EM
dihydrate, powder compacts were prepared and evaluated by plotting their crushing
strength versus compaction pressure (V, Fig. 7). The commercial sample, reference
crystals and the crystals grown in the presence of 0.45 wt% of HPMC all produced weak
compacts with a high capping tendency, regardless of the compaction pressure applied.
For the crystals obtained in the presence of 4.5 wt% of HPMC, a linear relationship
between the crushing strength of the compacts and the compaction force was observed at
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lower compaction forces (<8 kN); upon further increase in the compaction force the
relationship was inverse. The crushing strength of the compacts loaded with the crystals
grown in the presence of 2.25 wt% of HPMC constantly increased with increasing
compaction force.
Compression cycles can be considered as a sequence of three steps: (1) rearrangement
and packing of powder in the die, (2) fragmentation and/or plastic deformation of the
particles, and (3) elastic recovery of the compact (Jetzer et al., 1983). Overall, behaviour
of the material during these steps is defined by internal structure of the crystal (Roberts et
al. 1995; Sun and Grant, 2001; Feng and Grant, 2006). Meanwhile, crystal habit may
influence the compaction profile through its effect on the initial particle rearrangement.
More specifically, the relative orientation of the crystallites during compression and hence
the contact area between them are influenced by the crystal habit (Bandyopadhyay and
Grant, 2002). More rounded or more equidimensional crystals (such as crystals obtained in
the presence of 2.25 wt% of HPMC) are likely to orient randomly, while less
equidimensional crystals (obtained in the presence of 4.5 wt% of the polymer) tend to
pack preferentially with their longer dimension(s) oriented normally to the compression
axis. Owing to differences in surface free energy and thus in physicomechanical properties
of crystal faces arising from the differences in their surface chemistry (Lee and Myerson,
2006), it is assumed that the crystals grown in the presence of 2.25 wt% of HPMC with
random orientation during compression possess improved mechanical properties, as
compared  to  those  of  the  crystals  precipitated  in  the  presence  of  4.5  wt%  of  HPMC.  In
addition, the adsorbed polymer may increase lattice strain, reducing the energy required
for plastic deformation and thus leading to improved tableting performance.
In conclusion, this study reports a practical approach, based on additive-induced
crystal habit modification, to enhancing compaction behaviour of APIs. Future studies
should employ crystal chemistry analysis and various prediction models (Plumb et al.,
2005; Shao et al., 2007) to provide insight into the relationship between the modified
crystal habit and tabletting performance of the model API.
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6. CONCLUSIONS
Solid state properties and interconversion pathways among the different crystalline forms
of EM (dihydrate, dehydrate, and anhydrate) and BF (anhydrate and monohydrate) are
reported. This study highlights structural and analytical aspects of the isomorphic
dehydrate of EM that has long been a source of a large number of inconsistencies and
misinterpretations in the literature. BF monohydrate is described for the first time. Overall,
this information enables improved understanding and control of the solid-state of these
APIs during processing and storage.
Upon polymorph screening, a high solvate-forming propensity of EM was observed.
Moreover, the formation of isomorphic solvates with structurally related solvents such as
acetone and methylethyl ketone was discovered. The solid-state properties of the EM
solvates are reported and the solvent compositions that yield the thermodynamically stable
dihydrate form are defined.
The mechanisms of dehydration of EM dihydrate and hydrate formation of BF
anhydrate were elucidated. Dehydration of EM dihydrate is a solid-state reaction that
follows a topotactic mechanism and results in an isomorphic dehydrate. Hydrate formation
of BF takes place via a solvent-mediated route and thus this phase transformation can
occur during water-based processes (e.g. recrystallization, wet granulation, film-coating).
An understanding of the mechanisms involved in these phase transformations provides a
scientific basis for designing the manufacturing processes.
Hot-melt processing of high melting crystalline APIs or excipients with PEG 6000 can
induce a solvent-mediated transformation, with the polymer acting as a solvent. This
knowledge can be extremely beneficial in predicting the performance and stability of the
final dosage form as well as in the design of the process.
Morphological crystal engineering provides an effective tool for tailoring technological
properties of pharmaceuticals solids. By using pharmaceutically accepted excipients as
crystal habit modifiers toxicity and/or environmental concerns can be overcome. This also
supports the concept of crystallization as the very first formulation step.
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